February 23, 2024

24/7 Market News Snapshot 08 Jan, 2024 – Ardelyx Inc. (NYSE: ARDX)

Press Release

Last Price: $0.00 ▼ -1.59% -0.14  (2024-02-23 16:00) (Market Closed)

DENVER, Colo., 08 Jan, 2024 (www.247marketnews.com) – **Ardelyx Inc. Enjoys Phenomenal Market Success as Shares Surge amid IBSRELA® Revenue Predictions**

In a demonstration of market confidence, Ardelyx Inc. has seen its stock price climb by an impressive 16.84%, reaching $7.1975. The energetic uptick was powered by a trading volume that soared to over 4.4 million shares, as positive investor outlook propelled the stock $1.0375 higher in a single day of robust trading activity.

Simultaneously, expansive growth prospects are on the horizon for Ardelyx Inc., following an optimistic projection for its flagship drug, IBSRELA® (tenapanor). Financial analysts anticipate the treatment for irritable bowel syndrome with constipation (IBS-C) to achieve a landmark peak in annual net product sales, potentially crossing the $1 billion threshold in the U.S. market.

This remarkable financial forecast is credited to Ardelyx’s comprehensive commercial strategy and the encouraging reception of IBSRELA® among healthcare professionals and patients. Endorsements rest on the drug’s proven effectiveness to enhance the quality of life for individuals with IBS-C. These developments are framed within the context of targeted marketing initiatives and educational programs that have not only expanded the drug’s market share but also solidified Ardelyx’s leadership in the niche of gastrointestinal treatments.

“The ascent of IBSRELA® represents a transformational era for Ardelyx, as it promises to become a high-impact, blockbuster drug,” said the CEO of Ardelyx Inc. “Our teams have been central to fostering this growth, and we are steadfast in our mission to continue its trajectory of success, providing vital solutions for those managing IBS-C.”

This news has been warmly received by the investor community, heralding it as an indicator of sustained profitability and continued growth potential for Ardelyx Inc. With IBSRELA® driving Ardelyx’s portfolio, the company exhibits robust commercial prowess and a compelling value proposition for both patients and shareholders alike.

For further details on Ardelyx Inc. and its medical solutions, including IBSRELA®, please visit our website [insert web address].

**About Ardelyx Inc.**
Ardelyx Inc. is a premier biopharmaceutical firm passionately engaged in the development and commercialization of innovative therapies. We pride ourselves on addressing the complex challenges within the realms of nephrology and cardiology, delivering transformative medicines to enhance patient lives globally.

**Cautionary Note Regarding Forward-Looking Statements**
This press release may contain statements that are forward-looking, which could involve specific risks and uncertainties. The words “project”, “expect”, “anticipate”, and similar expressions are intended to identify forward-looking statements. While these statements reflect our current expectations and beliefs, they are not guarantees of future performance, and actual outcomes may differ materially. Ardelyx undertakes no obligation to publicly update any forward-looking statement.

*For media inquiries, please contact:*
Ardelyx Inc. Media Relations Department
[insert email address]
[insert phone number]

**END OF PRESS RELEASE**
Connect with 24/7 Market News:
www.247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.